HOLOCLARA
Holoclara is a immunotherapy company that offers autoimmune disorders with nematode derived molecules.
HOLOCLARA
Social Links:
Industry:
Therapeutics
Founded:
2017-01-01
Address:
Los Angeles, California, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Font Awesome
Current Employees Featured
Founder
Investors List
Kairos Ventures
Kairos Ventures investment in Seed Round - Holoclara
More informations about "Holoclara"
Holoclara Team Page — HOLOCLARA
PROFESSOR OF BIOLOGY, CALTECH . Paul Sternberg is a co-founder of Holoclara and is a Professor at Caltech. He is an expert in the field of genetics, using computational biology on the model organism, C. elegans, as well as …See details»
Overview — HOLOCLARA
Holoclara is using our discovery engine, a unique solution, to isolate and identify worm derived molecules to help the millions of people suffering from allergic and autoimmune diseases. Our …See details»
Holoclara - Crunchbase Company Profile & Funding
Holoclara uses a proprietary discovery engine to isolate and identify molecules from worms that can limit inflammation and promote tissue repair. Clinical …See details»
Holoclara Company Profile 2024: Valuation, Funding & Investors
Holoclara General Information Description. Provider of immunotherapy services intended to bring relief to people suffering from autoimmune disorders. The company offers a range of services …See details»
Holoclara Announces $16 Million Series A Financing to ... - BioSpace
Jun 27, 2024 PASADENA, Calif.--(BUSINESS WIRE)-- Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergies and autoimmune …See details»
Holoclara gains Series A financing for worm-derived …
Jun 28, 2024 Holoclara is also expanding its discovery engine, which is dedicated to isolating specific molecules from worms that exhibit therapeutic potential. The company’s platform is based on research by CEO and co …See details»
Exclusive: Holoclara raises $16 million Series A to …
Jun 27, 2024 Holoclara has raised $16 million for its Series A, Fortune has exclusively learned. Bold Capital Partners led the round, with participation from Horizons Ventures, Tarrasque, Endurance28, Freeflow ...See details»
MedNews: Holoclara closes $16 Million financing to advance …
Jun 30, 2024 Peter Barton Hutt, former Chief Counsel for the Food and Drug Administration, joins Holoclara’s Board of Directors Holoclara, a biotechnology company pioneering the …See details»
Holoclara Announces $16 Million Series A Financing to Advance a ...
Jun 27, 2024 Holoclara is the first biotechnology company to create safe, orally available worm-derived therapies designed to provide relief to millions of people living with allergic and …See details»
Holoclara: $16 Million Secured To Develop Worm …
Jul 10, 2024 Holoclara, a biotechnology company that is pioneering the development of worm-derived therapies for allergies and autoimmune disorders, today announced the completion of an oversubscribed $16 million Series A …See details»
Term Sheet — HOLOCLARA
Jun 27, 2024 by the time she cofounded Holoclara in 2017. And now, the company just hit a milestone: Holoclara has raised $16 million for its. Series A, Fortune has exclusively learned. …See details»
Holoclara Announces $16 Million Series A Financing to Advance a ...
Jun 27, 2024 Holoclara Announces $16 Million Series A Financing to Advance a Breakthrough Class of Worm-Derived Therapies for Allergic and Autoimmune Disease Business Wire Thu, …See details»
Holoclara - Funding, Financials, Valuation & Investors - Crunchbase
Holoclara is a immunotherapy company that offers autoimmune disorders with nematode derived molecules. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Holoclara Announces $16 Million Series A Financing to Advance a ...
• Peter Barton Hutt, former Chief Counsel for the Food and Drug Administration, joins Holoclara’s Board of Directors PASADENA, Calif., June 27, 2024-- Holoclara, a biotechnology company …See details»
RePORT 〉 RePORTER
Awardee Organization HOLOCLARA, INC. Description. Abstract Text. The current armamentarium of asthma drugs undoubtedly saves numerous lives every year but remains …See details»
Worm-Derived Drugs May One Day Treat Allergic and …
Dec 13, 2023 Holoclara’s initial program is replicating the language of worms using traditional synthetic chemistry to possibly treat, and potentially cure, many common diseases with orally …See details»
Science — HOLOCLARA
Many studies have shown that worms impart a therapeutic effect on the mammalian immune system. Specifically, their secretions and excretions have demonstrated anti-inflammatory …See details»
Co-Founder and CEO, Holoclara | Aspen Ideas - Aspen Ideas Festival
Andrea Choe is co-founder and CEO of Holoclara, the first company to create safe, orally available worm-derived therapies. While pursuing her doctorate at the California Institute of …See details»
Holoclara - Contacts, Employees, Board Members, Advisors
Holoclara is a immunotherapy company that offers autoimmune disorders with nematode derived molecules.See details»